Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
No Combination approved
CJC-1295 and Ipamorelin offer smoother and more efficient growth hormone delivery
Test results are documented and traceable to the specific batch supplied
Research in models of bone disease has studied the peptides possible to prevent or reverse bone loss
Pfeilschifter J, Diel I, Pilz U, Brunotte K, Naumann A, Ziegler R: Mitogenic responsiveness of human bone cells in vitro to hormones and growth factors decreases with age
Safety Considerations and Contraindications Who Should Avoid CJC-1295 Ipamorelin Contraindications : Active cancer diagnosis (growth hormone can stimulate existing tumors) Pregnancy or breastfeeding Severe cardiovascular disease Uncontrolled diabetes Children and adolescents under 18 Potential Drug Interactions CJC-1295 Ipamorelin may interact with: Insulin and diabetes medications (can affect blood sugar) Corticosteroids (may blunt GH response) Thyroid medications (may require dose adjustments) Other hormone therapies Medical Supervision Requirements Consult healthcare providers before starting if you have: Diabetes or blood sugar issues Cardiovascular conditions History of cancer Current prescription medications Sleep disorders Our Clinics Experience with CJC-1295 Ipamorelin Dosing Through extensive clinical experience with CJC-1295 Ipamorelin protocols, weve observed optimal results with 200 mcg of each peptide administered before bed, 5 days per week
US$ 23.70
US$ 28.94
US$ 29.51
US$ 24.51
US$ 24.31
